Dividends Novo Nordisk’s Capital Discipline Meets a Market That’s Still Not Convinced
The arithmetic of shareholder returns at Novo Nordisk tells a story of patience under pressure. The Danish drugmaker has plowed 8.08 billion Danish kroner into buying back its own B-shares...